LeMaitre director awarded 477 LMAT shares

LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock. On February 26, 2026, she acquired 476 shares of common stock at a price of $0.0000 per share as a grant or award. She also acquired 1 additional common share through the exercise of a dividend equivalent right linked one-for-one to common stock. These transactions stem from a Performance Share Unit award originally granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remaining portions scheduled to vest in equal annual installments on the grant date anniversaries over the next two years.

Insider Trade Summary

1 shares exercised/converted

Exercise 3 txns

Insider SHADAN MARTHA

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	1	$0.00	$0.00
Grant/Award	Common Stock	476	$0.00	$0.00
Exercise	Common Stock	1	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 2.8963 contracts (Direct); Common Stock — 2,962 shares (Direct)

Footnotes (3)

F1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 1/3 upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next two years.
F2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
F3. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did LMAT director Martha Shadan report on February 26, 2026?

Martha Shadan reported acquiring LMAT equity on February 26, 2026. She received 476 shares of common stock as a grant and 1 additional share through the exercise of a dividend equivalent right, all at a stated price of $0.0000 per share.

How many LeMaitre Vascular (LMAT) shares did Martha Shadan acquire in this Form 4?

Martha Shadan acquired 477 LMAT common shares in total. This included a 476‑share grant described as a grant, award, or other acquisition, plus 1 share received upon conversion of a dividend equivalent right tied one-for-one to common stock.

What is the source of the LMAT shares reported by Martha Shadan in this filing?

The reported LMAT shares come from a Performance Share Unit award granted on December 6, 2024. One-third vested after the performance condition was determined satisfied on February 26, 2026, generating common shares and related dividend equivalent rights.

What are dividend equivalent rights in Martha Shadan’s LMAT Form 4 filing?

Dividend equivalent rights in this filing are derivative rights economically equivalent to one LMAT common share each. They were released in connection with the vesting of the Performance Share Unit award and converted into common stock on a one-for-one basis on February 26, 2026.

How does the LMAT PSU vesting schedule affect Martha Shadan’s reported equity awards?

The Performance Share Unit award vested one-third when the performance condition was satisfied on February 26, 2026. The remaining two-thirds are scheduled to vest in equal annual installments on the December 6 grant date anniversaries over the following two years, influencing future equity settlements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/02/2026 - 09:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHADAN MARTHA

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

01803

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		476⁽¹⁾	A	$0	2,961	D
Common Stock	02/26/2026		M		1⁽²⁾	A	$0⁽²⁾	2,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽³⁾	02/26/2026		M			1⁽³⁾	⁽³⁾	⁽³⁾	Common Stock	1	$0	2.8963	D

Explanation of Responses:

1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 1/3 upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next two years.

2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

3. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR